ReviewEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology2024
Drug-eluting devices for lower limb peripheral arterial disease.
Review in EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Performance of stenting in femoropopliteal disease: a systematic literature review and meta-analysis of proportions.Journal of comparative effectiveness research · 2026Pooled it
- When should clinical practice guidelines change? A critical appraisal of the ESVS focused update on paclitaxel-coated devices after SWEDEPAD 2.CVIR endovascular · 2026Article
- Drug-coated balloon angioplasty for coronary and peripheral artery disease: latest evidence and clinical indications.Nature reviews. Cardiology · 2026Review
- Comparative Efficacy of Endovascular Interventions for Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis.Cardiovascular and interventional radiology · 2026Review
- Paclitaxel Efficacy in Dialysis-Dependent Peripheral Artery Disease: A National Cohort Analysis.Journal of the American Heart Association · 2026Article
- Predictors of target lesion restenosis after endovascular therapy for lower-extremity atherosclerotic peripheral artery disease: a real-world single center cohort.Journal of cardiothoracic surgery · 2026Article
- Computational Optimization of a Stent for the Femoropopliteal Artery.Annals of biomedical engineering · 2026Article
- Safety of paclitaxel-coated devices in patients with peripheral artery disease: an updated systematic review and meta-analysis of randomized controlled trials.EClinicalMedicine · 2026Article
- Article
- Five-Year Outcomes of Paclitaxel-Coated Balloons in Patients with Diabetes from the BIOLUX P-III Single-Arm Study.Vascular health and risk management · 2026Article
- Comparable clinical characteristics and outcomes of patients undergoing endovascular treatment for aorto-iliac or femoropopliteal lesions.Cardiovascular intervention and therapeutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peripheral arterial disease is the third leading cause of cardiovascular morbidity after coronary artery disease and stroke. Lower limb peripheral arterial disease commonly involves infrainguinal arteries, may impair walking ability (intermittent claudication) and may confer a significant risk of limb loss (chronic limb-threatening ischaemia), depending on the severity of ischaemia. Endovascular treatment has become the mainstay revascularisation option in both the femoropopliteal and the below-the-knee arterial segments. After crossing and preparing the lesion, treatment results in these arterial segments can be enhanced by using drug-coated devices (drug-eluting stents and drug-coated balloons) that mitigate the occurrence of restenosis. As for other medical devices, the use of drug-eluting devices is based on their demonstrated safety and efficacy profiles when applied in the distinct segments of the lower limb vasculature. In this state-of-the-art narrative review we provide an overview of the safety and efficacy of drug-coated devices when used in the femoropopliteal and below-the-knee arterial segments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.